The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.
about
In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2)Safety of statins: an updateApplication of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Depression induces poor prognosis associates with the down-regulation brain derived neurotrophic factor of serum in advanced small cell lung cancerPharmacogenetics of drug transporters in the enterohepatic circulation.Clinical response to statins: mechanism(s) of variable activity and adverse effects.ABCG2 transporter: therapeutic and physiologic implications in veterinary species.Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Pharmacogenomics of lipid-lowering therapies.Lipid-lowing pharmacogenomics in Chinese patients.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.PharmGKB summary: very important pharmacogene information for ABCG2.Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Transporters.Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.
P2860
Q28540667-40A97935-0D04-4694-81E4-C584BC95BC57Q33949312-1BFA095E-6ACC-4CFD-B296-C306AA28A664Q33994570-19F2346A-6446-4EAE-8ACD-66E1467E3D4CQ34680467-E0FE759B-E331-44B9-9630-F24DE53946F1Q36020304-39B01333-8A28-41C2-8311-EA810158A7CBQ36233941-2500C997-13B9-4234-B303-07245BEA841BQ37699163-6060C8EE-BAC9-4F39-8B56-334897BF73C3Q37880875-DD22AD59-3101-4FD9-A97D-BCFA1B594311Q37881964-29A85A55-A3E7-4379-AB5E-26BCDA639F3BQ37885400-DC4C4F50-C382-412E-B515-DE62CC1EA799Q38051447-AADBA1A3-A906-49AC-B3CA-A2CE3DB7B1C2Q38071700-7CA6DB1E-7E18-42E2-9B01-5C92679DF91BQ38112823-AB04C91C-FD84-4E6D-B000-7DF1F1106A6EQ38129422-CE08BF0D-0347-421B-B9CF-5470E93A324DQ38155218-B8E4E30D-790F-4B25-B932-87052F40827AQ38305576-990A73EE-BBFE-42FD-A612-DE98F0B950D9Q38888369-AAAA11B0-DBD7-43B8-B5E4-9A33949408B1Q40129655-E2758A07-B949-439C-B475-ADD39CF8E06AQ46018199-C8F36F28-E9BE-4557-9F45-87B302D5D5E0Q46062183-BA5DAA54-D916-4A33-9E6F-7E35B0274202Q48202863-84437BDE-C93E-4901-B717-B579B86ED39AQ51481319-7DFF0575-3221-4F3B-8178-BAA48153B3C2Q52718401-6132D46A-DC3E-44FA-A53C-6BE7ADFDCB05Q55518566-F8A94C28-FDFE-46DC-80D3-BE297B2DC442
P2860
The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The ABCG2 transporter and its ...... d-lowering effects of statins.
@en
The ABCG2 transporter and its ...... d-lowering effects of statins.
@nl
type
label
The ABCG2 transporter and its ...... d-lowering effects of statins.
@en
The ABCG2 transporter and its ...... d-lowering effects of statins.
@nl
prefLabel
The ABCG2 transporter and its ...... d-lowering effects of statins.
@en
The ABCG2 transporter and its ...... d-lowering effects of statins.
@nl
P2093
P2860
P1476
The ABCG2 transporter and its ...... d-lowering effects of statins.
@en
P2093
Brian Tomlinson
Kenneth K W To
Valiant W L Mak
P2860
P356
10.1517/17425255.2011.538383
P407
P577
2010-11-23T00:00:00Z